Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deutetrabenazine in Huntington Disease
NCT04713982Phase 3Active, not recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Nov 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deutetrabenazine in Huntington disease (HD), sponsored by Vanderbilt University Medical Center. Started Nov 2021; status: active, not recruiting.
02
Drugs
deutetrabenazine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT04713982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04713982.